Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up – Should You Buy?

Zealand Pharma A/S (OTCMKTS:ZLDPF)’s stock price gapped up prior to trading on Tuesday. The stock had previously closed at $34.5965, but opened at $36.80. Zealand Pharma A/S shares last traded at $36.75, with a volume of 600 shares changing hands.

Analyst Ratings Changes

A number of brokerages recently issued reports on ZLDPF. Wells Fargo & Company restated an “overweight” rating on shares of Zealand Pharma A/S in a research report on Thursday, August 13th. Zacks Research upgraded Zealand Pharma A/S from a “hold” rating to a “strong-buy” rating in a report on Monday, October 12th. Jefferies Financial Group lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Finally, Barclays downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 8th. Two equities research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and eight have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Hold”.

Zealand Pharma A/S Trading Down 0.3%

The company has a quick ratio of 13.98, a current ratio of 13.98 and a debt-to-equity ratio of 0.02. The business’s fifty day moving average is $39.26 and its 200-day moving average is $47.12. The stock has a market capitalization of $2.63 billion, a PE ratio of 6.09 and a beta of 0.99.

About Zealand Pharma A/S

Zealand Pharma A/S is a biotechnology company headquartered in Copenhagen, Denmark. Founded in 1998, it discovers and develops peptide-based medicines, with a focus on metabolic diseases and rare conditions. The company’s portfolio has included Zegalogue (dasiglucagon), an injectable treatment approved in the United States for severe hypoglycemia in people with diabetes. Zealand also develops investigational medicines for areas such as obesity, liver disease and rare gastrointestinal disorders, and works with pharmaceutical partners to advance and commercialize selected programs.